Previous clinical trials that investigated the safety and efficacy of semaglutide did not report significant vision complications except for the SUSTAIN-6 trial and a subsequent meta-analysis of ...

Enhanced weight loss effects of NT-0796 and semaglutide in combination ...

Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related ...

The prospect of a pill rather than an injection is obviously appealing to some people, but will fear of needles be enough to ...

1."We apparently don't know precisely how our bodies can distinguish gas from poop. We have some ideas, we know there are a ...

The 40-week SUSTAIN 7 trial investigated the efficacy and safety of 0.5 mg semaglutide compared with 0.75 dulaglutide and 1.0 mg semaglutide compared with 1.5 mg dulaglutide, when added to metformin.

More than 7 million people would have gained coverage to the medicine, CMS said when it proposed the rule.

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Felix. In this article, we will summarize the bulls’ thesis on NVO.

The future of telehealth is trust, combined with patient education. As the market matures, all parties — providers, ...